Blood-brain barrier leaks, which are observed in Parkinson's disease and other neurodegenerative diseases, can prompt the accumulation of amyloid plaques associated with Alzheimer's disease and should be considered an Alzheimer's biomarker and likely drug target, according to a review article in Nature Neuroscience. "Cognitive impairment, and accumulation in the brain of the abnormal proteins amyloid and tau, are what we currently rely upon to diagnose Alzheimer's disease, but blood-brain barrier breakdown and cerebral blood flow changes can be seen much earlier," said researcher Dr. Berislav Zlokovic.
A study in the Annals of Neurology showed that vascular, amyloid/tau, TAR DNA-binding protein 43/hippocampal sclerosis and neocortical Lewy body pathology pathways were individually tied to a significant percentage of the link between age and dementia and collectively accounted for all variance in age-related increases in the odds of dementia. Researchers also found the interdependence of the amyloid/tau, TDP-43/hippocampal sclerosis and neocortical Lewy body pathways, which accounted for 68% of the correlation between age and dementia.
Researchers found that African-Americans, who are more likely to be affected by aging-related conditions such as Alzheimer's disease, had significantly lower circulating levels of the mitochondrial peptide humanin, compared with whites, and mice that received humanin injections had delayed aging-related cognitive decline. The findings in Scientific Reports suggest that humanin-related therapies may be used to treat Alzheimer's disease and other illnesses tied to aging.
Young adults were more able to accurately recall information and had increased functional connectivity between the cortical brain regions and the hippocampal dentate gyrus, which are involved in memory processing, in functional MRI scans, after undergoing 10 minutes of mild exercise, compared with having no exercise, Japanese researchers reported in the Proceedings of the National Academy of Sciences. The benefits of a short light exercise protocol in cognition may also be observed in older adults, said researcher Hideaki Soya.
Cerveau Technologies and Ionis Pharmaceuticals have entered a research collaboration deal for the use of Cerveau's F-18 MK-6240, an investigational PET tracer for imaging neurofibrillary tangles in the brain, as a biomarker in Ionis' neurodegenerative disease research and in assessing how therapies affect neurodegenerative disease progression.
The FDA granted accelerated approval for Verastem Oncology's Copiktra, or duvelisib, as a treatment for adult patients with small lymphocytic lymphoma or relapsed/refractory follicular lymphoma or chronic lymphocytic leukemia following two or more lines of therapy.
Researchers found that only 46% of quality improvement studies used iterative cycles for intervention refinement, with iterative cycle use linked to programs aimed at boosting QI expert support, processes, unintended effect reporting and explicit statement of iterative cycle use. The findings in a radiology journal, based on data from 44 QI studies from 2008 to 2015, also showed that inadequate scientific rigor was characterized by failure to describe unintended effects, discuss limitations and report baseline data.
House and Senate lawmakers finalized a major opioid legislative package late Monday, and it won't include a technical change to Medicare Part D's "doughnut hole" language pushed by pharmaceutical firms. The final package includes a measure by Sen. Rob Portman, R-Ohio, that would temporarily lift restrictions on use of Medicaid funds for inpatient addiction treatment.
Medical practices are advised to provide adequate EHR training for physicians, seek help from physicians in EHR development and clinical workflow design, and establish an EHR governance process, according to a white paper released by the Stanford University School of Medicine. The document also recommends presenting data in a user-friendly format, reducing clinician burden by offloading non-essential EHR tasks to other staff, and allowing patients to digitally maintain their EHRs.
The 2019 SNMMI Mid-Winter and ACNM Annual Meeting -- Jan. 17-19, 2019, in Palm Springs, Calif. -- is ready to get you to the heart of nuclear medicine. With a featured track on nuclear cardiology, combined with a small, focused meeting environment to inspire collaboration and discussion and a hands-on approach to learning, you'll walk away with tangible outcomes to optimize how cardiovascular imaging helps you treat your patients. Sign up today for updates.Learn more about the 2019 meeting.
Abstracts are currently being accepted for the 2019 ACNM Annual Meeting, taking place Jan. 17-19, 2019, in Palm Springs, Calif. Early-career professionals are invited to submit clinical or scientific abstracts on: nuclear cardiology, aspects of clinical and basic science in nuclear medicine, correlative imaging in nuclear medicine and radiology, nuclear pharmacy and physics, radionuclide therapy, or quality and safety in nuclear medicine. Get started today.
Tests are a gift. And great tests are a great gift. To fail the test is a misfortune. But to refuse the test is to refuse the gift, and something worse, more irrevocable, than misfortune.
Lois McMaster Bujold, writer
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items above are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at email@example.com.